Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Show details Contents Appendix 5Summary of Indirect Comparisons of Second-Line Therapy Introduction There is direct evidence comparing semaglutide to sitagliptin and dulaglutide in patients inadequately controlled on one oral antidiabetic drug (OAD), and to exenatide or insulin glargine in patients with inadequate glycemic control with one or two OADs, however data are lacking for other comparators
Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should avoid these treatments
The platform's pricing and convenience make it accessible to people who might otherwise not have access to these medications
Accessed November 13, 2023
In contrast, Ozempic, while globally approved for diabetes management, is primarily intended to improve glycaemic control
US$ 27.35
US$ 27.21
US$ 22.51
US$ 25.12
US$ 22.97
US$ 25.35
US$ 25.40
US$ 26.95
